<code id='F48C6F9971'></code><style id='F48C6F9971'></style>
      • <acronym id='F48C6F9971'></acronym>
      <center id='F48C6F9971'><center id='F48C6F9971'><tfoot id='F48C6F9971'></tfoot></center><abbr id='F48C6F9971'><dir id='F48C6F9971'><tfoot id='F48C6F9971'></tfoot><noframes id='F48C6F9971'>
      • <optgroup id='F48C6F9971'><strike id='F48C6F9971'><sup id='F48C6F9971'></sup></strike><code id='F48C6F9971'></code></optgroup>
        5. <b id='F48C6F9971'><label id='F48C6F9971'><select id='F48C6F9971'><dt id='F48C6F9971'><span id='F48C6F9971'></span></dt></select></label></b><u id='F48C6F9971'></u>
          <i id='F48C6F9971'><strike id='F48C6F9971'><tt id='F48C6F9971'><pre id='F48C6F9971'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / hotspot      
           
     
           
      
          hotspot 
           
      
           
      
           
       2025-09-30 21:02:31 
   
      
           
      
           
                        
          hotspot  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：951
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'
                                
                            
          Next article：  
                                      
                                          BioMarin wins approval for gene therapy to treat hemophilia A
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles